Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone, etoposide, and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving bortezomib together with combination
chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when
given together with mitoxantrone, etoposide, and cytarabine in treating patients with
relapsed or refractory acute myeloid leukemia.